Testing orelabrutinib for ALS
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests whether a pill called orelabrutinib can slow down ALS. It is an early-stage study to check safety and see if it may help people with ALS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a confirmed diagnosis of ALS, and it started within the last 3 years.
- Your ALS symptoms are not too severe yet (ALSFRS-R score of 35 or higher).
- Your breathing is still good (no need for breathing support during the day).
- You can swallow pills and do not need a feeding tube.
- You have not had cancer, active infections like HIV or hepatitis, or recent major surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a daily pill called orelabrutinib to see if it can slow disability progression in people with primary progressive multiple sclerosis (PPMS). It may be an option for patients whose symptoms have been getting worse over the past two years.
This study tests an oral medication called orelabrutinib for people whose multiple sclerosis has changed from relapsing-remitting to secondary progressive. The goal is to see if it can slow down disability worsening that happens even without relapses.
This trial tests an oral targeted therapy (orelabrutinib) for people with early-stage marginal zone lymphoma who have not yet had treatment. The goal is to see if this medication can control the cancer with fewer side effects than standard treatments.
This trial tests a new drug called orelabrutinib given with standard chemotherapy for a specific subtype of diffuse large B-cell lymphoma (DLBCL) called MCD. The treatment aims to improve outcomes and is followed by a maintenance phase with orelabrutinib alone.
This trial tests a new targeted drug (orelabrutinib) with or without another drug that targets CD20 (a protein on some immune cells) for people with untreated marginal zone lymphoma. It aims to see if this combination works better than other treatments and may be an option for those who cannot have radiation.
This trial tests a new pill (orelabrutinib) combined with a standard chemotherapy regimen (called BG) as your first treatment for CLL or SLL. The goal is to see if this combination works well and is safe for people like you who have not been treated before.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.